$3.49
-0.04[-1.13%]
At close: Apr 30
$3.49
0[0.00%]
PreMarket: 8:41AM EDT
Relmada Therapeutics
(NASDAQ:RLMD)Relmada Therapeutics Stock (NASDAQ:RLMD), Analyst Ratings, Price Targets, Predictions
Relmada Therapeutics Inc has a consensus price target of $16.17, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from Mizuho, SVB Leerink, and Goldman Sachs on June 15, 2023, January 23, 2023, and October 14, 2022. With an average price target of $14.67 between Mizuho, SVB Leerink, and Goldman Sachs, there's an implied 320.25% upside for Relmada Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Mizuho
SVB Leerink
Goldman Sachs
Guggenheim
Oppenheimer
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Relmada Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 06/15/2023 | RLMD | Buy Now | Relmada Therapeutics | $3.49 | 644.99% | Mizuho | Vamil Divan | → $26 | Reiterates | Buy → Buy | Get Alert |
| 01/23/2023 | RLMD | Buy Now | Relmada Therapeutics | $3.49 | 186.53% | SVB Leerink | Marc Goodman | $42 → $10 | Maintains | Outperform | Get Alert |
| 10/14/2022 | RLMD | Buy Now | Relmada Therapeutics | $3.49 | 129.23% | Goldman Sachs | Andrea Tan | → $8 | Downgrade | Buy → Neutral | Get Alert |
| 10/14/2022 | RLMD | Buy Now | Relmada Therapeutics | $3.49 | — | Guggenheim | Yatin Suneja | — | Downgrade | Buy → Neutral | Get Alert |
| 10/13/2022 | RLMD | Buy Now | Relmada Therapeutics | $3.49 | — | Oppenheimer | Jay Olson | — | Downgrade | Outperform → Perform | Get Alert |
| 09/23/2022 | RLMD | Buy Now | Relmada Therapeutics | $3.49 | 2220.92% | Goldman Sachs | Andrea Tan | $49 → $81 | Maintains | Buy | Get Alert |
| 09/06/2022 | RLMD | Buy Now | Relmada Therapeutics | $3.49 | 1619.2% | Guggenheim | Yatin Suneja | $50 → $60 | Maintains | Buy | Get Alert |
| 05/09/2022 | RLMD | Buy Now | Relmada Therapeutics | $3.49 | 1733.81% | Oppenheimer | Jay Olson | $75 → $64 | Maintains | Outperform | Get Alert |
| 03/24/2022 | RLMD | Buy Now | Relmada Therapeutics | $3.49 | 1418.62% | Goldman Sachs | Ross Weinreb | $69 → $53 | Maintains | Buy | Get Alert |
| 12/20/2021 | RLMD | Buy Now | Relmada Therapeutics | $3.49 | 1103.44% | SVB Leerink | Marc Goodman | — | Maintains | Outperform | Get Alert |
| 11/18/2021 | RLMD | Buy Now | Relmada Therapeutics | $3.49 | 1332.66% | Mizuho | Vamil Divan | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Relmada Therapeutics (RLMD)?
The latest price target for Relmada Therapeutics (NASDAQ: RLMD) was reported by Mizuho on June 15, 2023. The analyst firm set a price target for $26.00 expecting RLMD to rise to within 12 months (a possible 644.99% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Relmada Therapeutics (RLMD)?
The latest analyst rating for Relmada Therapeutics (NASDAQ: RLMD) was provided by Mizuho, and Relmada Therapeutics reiterated their buy rating.
When was the last upgrade for Relmada Therapeutics (RLMD)?
There is no last upgrade for Relmada Therapeutics.
When was the last downgrade for Relmada Therapeutics (RLMD)?
The last downgrade for Relmada Therapeutics Inc happened on October 14, 2022 when Goldman Sachs changed their price target from N/A to $8 for Relmada Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Relmada Therapeutics (RLMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relmada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relmada Therapeutics was filed on June 15, 2023 so you should expect the next rating to be made available sometime around June 15, 2024.
Is the Analyst Rating Relmada Therapeutics (RLMD) correct?
While ratings are subjective and will change, the latest Relmada Therapeutics (RLMD) rating was a reiterated with a price target of $0.00 to $26.00. The current price Relmada Therapeutics (RLMD) is trading at is $3.49, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.